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Abstract
Background: Currently there are very few biomarkers to identify head and neck squamous cell carcinoma (HNSCC)
cancer patients at a greater risk of recurrence and shortened survival. This study aimed to investigate whether a
marker of systemic inflammation, the neutrophil-to-lymphocyte ratio (NLR), was predictive of clinical outcomes in a
heterogeneous cohort of HNSCC cancer patients.
Methods: We performed a retrospective analysis to identify associations between NLR and clinicopathological
features to recurrence free survival (RFS) and overall survival (OS). Univariate analysis was used to identify associations
and selected variables were included in multivariable Cox regression analysis to determine predictive value.
Results: A total of 145 patients with stage I-IV HNSCC that had undergone radiotherapy were analysed. Seventy-six of
these patients had oropharyngeal cancer and 69 had non-oropharyngeal HNSCC and these populations were analysed
separately. NLR was not associated to any clinicopathological variable. On univariate analysis, NLR showed associations
with RFS and OS in both sub-populations. Multivariable analysis showed patients with NLR > 5 had shortened OS in
both sub-populations but NLR > 5 only predicted RFS in oropharyngeal patients. Poor performance status predicted OS
in both sub-populations and current smokers had shortened OS and RFS in non-oropharyngeal patients.
Conclusions: The results show patients with NLR > 5 predict for shorter overall survival. Further prospective validation
studies in larger cohorts are required to determine the clinical applicability of NLR for prognostication in HNSCC
patients.
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Background
Head and neck squamous cell carcinoma (HNSCC) is an
aggressive disease and is the sixth most common cancer
worldwide, with approximately 650,000 cases diagnosed
worldwide annually and nearly 400, 000 deaths [1, 2].
HNSCC encompasses a wide variety of malignancies de-
riving from the mucosal epithelium of the upper aerodi-
gestive tract, including lip, oral cavity, paranasal sinuses,
nasal cavity, pharynx and larynx [3]. Data from the USA
indicates over two-thirds of patients present with
advanced-stage disease with either locoregional spread to
the lymph nodes or distant metastasis [4]. Historically, up
to 50 % of patients will experience locoregional recurrence
within 2 years of treatment with limited options for sal-
vage surgery or reirradiation [4, 5]. To date, there is lim-
ited molecular characterisation of the driver mutations of
the various subtypes of HNSCC, with human papilloma
virus (HPV), smoking and alcohol the only identified
causative agents. Therefore, understanding the biological
mechanisms that lead to cancer progression and identifi-
cation of prognostic factors are essential to improve the
clinical management of HNSCC.
A hallmark of many cancers, including HNSCC, is the
presence of a tumour promoting phenotype of chronic,
low-grade cancer-related inflammation [6–8]. Recent
studies have demonstrated that cancer-related inflamma-
tion derives from communication between the host and
tumour cells to develop a reciprocal interplay that often
results in systemic alterations, immune suppression and
evasion and malignant progression [6]. In HNSCC,
cancer-related inflammation is characterised by increased
circulating concentrations of pro-inflammatory cytokines
and acute phase reactant proteins (C-reactive protein,
serum amyloid A protein) that enhance the recruitment of
circulating neutrophils, monocytes [9], myeloid derived
suppressor cells (MDSC) [10, 11], and thus total leucocyte
numbers, whilst also inhibiting the recruitment of lympho-
cytes to the circulation. These changes lead to the develop-
ment of cancer-related syndromes, including fever, night
sweats, fatigue, cachexia and bone and muscle pain [12].
Over the last few years, there has been a proliferation in
clinical studies measuring the systemic inflammatory re-
sponse in cancer patients to identify patients with poor
prognosis (reviewed in [7, 13]). One of the key biomarkers
of systemic inflammation is the neutrophil-to-lymphocyte
ratio (NLR). An NLR score is obtained from a patients full
blood count by dividing the absolute neutrophil count by
the absolute lymphocyte count. An elevated NLR is
strongly related to other inflammatory markers, including
the Glasgow Prognostic Score, platelet-lymphocyte ratio
and elevated C-reactive protein levels, which have been as-
sociated with increased tumour burden and spread of dis-
ease. NLR is elevated in patients with laryngeal squamous
cell carcinoma compared to patients with benign and
precancerous lesions [14]. NLR is also an independent
prognostic marker of reduced overall survival (OS) in most
epithelial cancers [6, 15].
There have been numerous studies of the prognostic
role of NLR in various selected populations of HNSCC.
Small studies conducted in site-specific populations of
nasopharyngeal, oropharyngeal and oral cavity cancers,
showed elevated NLR was predictive of local and regional
recurrence or reduced progression free survival and/ or
poorer OS [16–20]. Investigations in small cohorts of un-
selected HNSCC patients have shown that HNSCC pa-
tients have an elevated NLR compared to healthy controls
and univariate analyses have associated elevated NLR to
recurrence, tumour and nodal stage [21–23]. A pilot study
in 46 unselected HNSCC patients was conducted by our
group and univariate analysis found that NLR was predict-
ive of shorter overall survival [24]. However, in these in-
vestigations of heterogeneous populations of HNSCC,
multivariable analysis of NLR as prognostic of recurrence
free survival (RFS) or OS was not undertaken.
Additionally, literature shows that HPV mediated over-
expression of p16 is an important marker of reduced risk
for recurrence and survival in HNSCC [25, 26]. Recent
in vitro and animal studies of cervical cancer have shown
that HPV positive (HPV+) cells are more efficient at pro-
ducing a pro-inflammatory tumour microenvironment
[27] leading to enhanced myeloid cell proliferation in the
bone marrow and spleen and increased recruitment of
leucocytes to the tumour [28]. Thus, the p16 status of a
patient may also alter the inflammatory response and con-
tribute both directly and indirectly to cancer outcomes.
Huang et al. [9] identified that p16 positive oropharyngeal
cancer patients with high circulating neutrophil levels
have a reduced OS and RFS. Interestingly, this association
was not seen in the p16 negative oropharyngeal patients.
Furthermore, higher levels of circulating lymphocytes
were predictive of improved RFS and marginally improved
OS in the p16 positive population but not in the p16 nega-
tive patients. Additionally, in a study by Ward et al. [29],
HPV+ oropharyngeal cancer patients with high or moder-
ate tumour infiltrating lymphocyte expression had signifi-
cantly improved survival compared to HPV+ low tumour
infiltrating lymphocytes and HPV negative (HPV-) pa-
tients regardless of lymphocyte expression. This would
suggest within the HPV+ oropharyngeal cancer popula-
tion the systemic and local inflammatory environment
may be important for determination of clinical outcomes.
In both studies there is a significant minority of HPV+ pa-
tients (20 %) that have poor OS. Identification of this high
risk group is important in an era of potential treatment
de-escalation and introduction of molecularly targeted
therapies. In addition, systemic inflammation has not
been well investigated as predictive biomarker for all
clinical outcomes in the non-oropharyngeal cancer
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population and identification of the high risk group of
patients is also essential.
In this retrospective analysis, we sought to investigate
whether NLR was an independent prognostic factor of RFS
and OS in a prospectively collected, non-selected HNSCC
population from one treatment centre. In addition we
investigated whether elevated NLR was associated with
clinicopathological features, including p16 status, which
may aid in treatment decisions.
Methods
Study design
The Northern Sydney Local Health District Human Re-
search Ethics Committee approved this study (1202-
056 M). Following local institutional ethical review board
approval, we conducted a retrospective analysis of patients
with HNSCC treated at the Northern Sydney Cancer
Centre between January 2005 and January 2012. Patients
were identified using a prospectively collected Head and
Neck Cancer Database [30] and informed written consent
was obtained from all patients. Eligible patients were
required to be 18 years or older, have pathologically con-
firmed primary mucosal squamous cell carcinoma, under-
gone radiotherapy based treatment, a minimum follow-up
of 12 months (unless deceased) and NLR recorded within
30 days prior to commencing radiotherapy. The patient
population included 145 patients with mucosal squamous
cell carcinoma of the lip and oral cavity, oropharynx, hypo-
pharynx, nasopharynx or larynx staged I-IV, who had been
treated with radiotherapy alone or in combination with sur-
gery and/or chemotherapy.
All patients were initially reviewed at a multidisciplin-
ary head and neck tumour board, which included oto-
laryngology surgeons, radiation oncologists and medical
oncologists who assigned the tumour stage and subse-
quent management. The patient demographics collected
for the present study included age, sex, Eastern Co-
operative Oncology Group performance status (ECOG
PS), smoking status (current, ex-smoker or non-smoker),
primary tumour location, American Joint Committee on
Cancer (AJCC; 6th Ed 2002) stage and treatment plan.
Additionally, radiotherapy dose, number of fractions and
the start and end date of radiotherapy were recorded for
each patient. The pre-treatment neutrophil and lympho-
cyte counts were obtained and the NLR calculated by
dividing the neutrophil count by the lymphocyte count.
A cut-off of 5 was used to categorise patients with high
(NLR > 5) or low (NLR ≤ 5) systemic inflammation. This
cut-off was chosen based on the systematic review of the
NLR literature in cancer which showed NLR > 5 as a pre-
dictive marker of cancer outcomes in over 30 studies of
15,500 cancer patients [7].When available, immunohisto-
chemistry for p16 was performed on formalin fixed paraf-
fin embedded sections using a specific mouse monoclonal
antibody (clone JC8, cat SC-56330, Santa Cruz CA, USA)
at a dilution of 1 in 10. Staining was interpreted by two
observers (TD, AJG) that were blinded to all other clinical
and pathological details. Diffuse, strong, full thickness
staining was categorised as p16 positive, while absent or
focal staining was categorised as p16 negative.
All procedures were in accordance with the ethical
standards of the institutional Human Research Ethics
Committee on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2000.
Treatment
Patients were treated on a standard department protocols
[30] either definitively with radiotherapy (stage I-II), che-
moradiotherapy (stage III-IV) or postoperatively in high
risk patients. Except for small field larynx treatments,
radiotherapy was delivered with sliding window intensity
modulated radiation therapy or volumetric modulated arc
therapy. For definitive patients treated with chemoradio-
therapy, the dose was 70 Gray (Gy) in 35 fractions with
weekly cisplatin (40 mg/m2) and 63 Gy and 56 Gy respect-
ively to the intermediate and low dose planning target vol-
umes. For patients treated with radiotherapy alone either
this fractionation was used or a hypofractionated schedule
of 66 Gy in 30 fractions [31]. Postoperative patients re-
ceived 60 Gy in 30 fractions. Treatment regimens provided
to patients remained consistent over the study period.
Statistical analysis
The primary objective of the study was to determine
whether NLR was a predictor of RFS and OS. Patients with
oropharyngeal cancer were analysed separately from other
tumour sites (lip and oral cavity, nasopharynx, hypophar-
ynx and larynx) due to known difference in disease eti-
ology and patients were assessed for differences between
these sub-populations. Additionally, patient demographics
were compared between p16 positive and negative oropha-
ryngeal patients. Patient demographics were also assessed
for differences in NLR status (NLR ≤ 5 vs NLR > 5) in the
total population and the two sub-populations. Statistical
tests used for the aforementioned univariate analyses
included independent samples t-test or Mann Whitney-U
test for continuous variables and χ2 test or Fisher’s exact
test for categorical variables.
Survival outcomes were determined from the start of
radiotherapy until the date of the event or death from
any cause (date of death obtained from hospital records).
The exploratory variables analysed in univariate and
multivariable survival analysis were assessed as follows:
age (continuous or categorised into 4 groups with equal
number of events for univariate survival analysis to as-
sess linear trends), sex (male vs female), ECOG PS (0 vs
1 or 2), smoking (current smokers compared to non-
smokers and ex-smokers), AJCC stage (I or II vs III or
Charles et al. BMC Cancer  (2016) 16:124 Page 3 of 13
IV), treatment (chemotherapy used vs other treatments),
and NLR (≤5 vs > 5). Patients who had surgery before
anti-cancer treatment were not compared to non-
surgical patients as surgeries were performed at multiple
hospital sites and various types of surgeries were per-
formed depending on the type of HNSCC. Additionally,
surgical risk factors were initially included, but due to
small numbers subsequently dropped from the analysis.
Variables were assessed with Kaplan Meier log rank test
and any variable with p value < 0.25 was included in a
final multivariable Cox regression model to determine
significant predictors of RFS and OS with adjustment
from other exploratory variables. All data from survival
analysis presented as hazard ratios (HR) ± 95 % confi-
dence interval (CI). Statistical tests were two sided with
α significance level of 0.05, and p values were not ad-
justed for multiple comparison testing. All analyses per-
formed using IBM SPSS for Windows, Version 20.
Results
Patient demographics for total population
A total of 145 patients were included in this retrospective
study and patient demographics are detailed in Table 1.
This is an expanded dataset that includes 40 patients from
a previous pilot study [24]. The median age was 63 years
(range, 28–86 years) and the majority of patients were
male (79 %) and most had ECOG PS 0 (70 %) or 1 (22 %).
Some patients continued smoking through their treatment
(26 %) but the majority were ex-smokers (42 %) or non-
smokers (30 %). The most common primary disease site
was oropharynx (52 %) and the majority of patients had
AJCC stage III or IV disease (70 %). Patients were treated
with definitive radiotherapy (12 %), postoperative radio-
therapy (20 %), definitive chemoradiotherapy (61 %), or
postoperative chemoradiotherapy (8 %). Of the 99 patients
treated with chemotherapy 89 received weekly cisplatin, 8
received cetuximab and one received carboplatin. Weekly
cisplatin was delivered for a median of 6 cycles. One pa-
tient did not complete a minimum of 5 cycles of cisplatin
and was changed to cetuximab due to toxicity. Radiation
treatment was completed without unscheduled breaks in
98 % of patients. Median (range) of neutrophils and lym-
phocytes was 5.10 (1.10-11.90) and 1.60 (0.20-10.70) x 109
cells/L respectively. And the median (range) of the calcu-
lated NLR was 1.60 (0.20-10.70) for the total population.
Material for p16 staining was available from 95 of 145 pa-
tients (66 %) patients. Systemic inflammation, as deter-
mined by elevated NLR > 5, was observed in 20 % of
patients. Of the 145 patients in this study, 37 patients
(26 %) developed a recurrence or metastasis. At the end of
the study, there were 35 deaths and a median 1-year OS
of 91 %. Median follow-up time of patients was 29 months
(range, 42 days to 7 years).
Comparison of demographics between oropharyngeal
patients and other primary sites
Table 1 also shows differences between oropharyngeal
cancer patients and other primary sites (classified as non-
oropharyngeal cancer patients). Patients with oropharyn-
geal cancer were significantly younger (p < 0.01) and had a
better ECOG PS (p < 0.001). There was a trend that
showed oropharyngeal patients had more limited tumours
(T1 or T2, 70 % vs 49 %), but more extensive nodal metas-
tases (N2 or N3, 57 % vs 32 %). Therefore, there was no
significant difference in final AJCC stage (p = 0.2). Oro-
pharyngeal patients rarely had surgery (7 % vs 55 %) and a
higher proportion of patients received chemoradiotherapy
(82 % vs 52 %). There were no differences in neutrophil
and lymphocyte counts in either sub-group. Additionally,
systemic inflammation was similar between both popula-
tions (NLR > 5, 21 % vs 19 %, p = 0.7). Finally, oropharyn-
geal patients were significantly more likely to show a
positive p16 status (84 % vs 20 %, p < 0.001).
In the oropharyngeal cancer patients with suitable tissue
available for testing, 37 out of 44 tested p16 positive
(84 %). This high percentage is consistent with the preva-
lence of p16 positivity in oropharyngeal patients over the
last 5 years at this hospital site (data not shown). Due to
the low numbers of p16 negative cases in the oropharyn-
geal cohort, it was deemed statistically invalid to investigate
relationships between NLR and p16 status. Additionally, as
the majority of patients were p16 positive there is limited
utility for the use of this marker in oropharyngeal popula-
tions and, furthermore, there were no significant differ-
ences in patient demographics between p16 tested and
non-tested oropharyngeal cancer cases (Additional file 1:
Table S1). Therefore, in subsequent analysis we combined
all oropharyngeal patients and excluded p16 status. In the
non-oropharyngeal cancer patients 10 out of 51 tested pa-
tients were p16 positive (20 %) with variable rates for each
major primary site (lip and oral cavity 4/9 (21 %), naso-
pharynx 1/1 (50 %), hypopharynx 0/9 (0 %) and larynx 5/
21 (24 %)). Due to the lack of consistent evidence for p16
status as a predictive biomarker in non-oropharyngeal can-
cers and low numbers in each cancer subsite, we have
also excluded p16 status from further analysis with clin-
ical outcomes.
NLR associations with patient demographics and survival
NLR associations to patient demographics in the total
population and oropharyngeal and non-oropharyngeal
sub-populations are detailed in Table 2. NLR was not as-
sociated with age, sex, ECOG PS, smoking status, tumour
site, tumour stage, nodal stage, AJCC stage or modality of
treatment for any population. Neutrophils, lymphocytes
and NLR were significantly associated with NLR status as
expected (all p values < 0.01).
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Table 1 Patient demographics
Characteristic All patients (N = 145)a Oropharyngeal (n = 76)a Non-oropharyngeal (n = 69)a p value*
Age, median years (range) 63 (28–86) 59.5 (32–83) 67 (28–86) <0.01
Sex, n (%) 0.5
Male 115 (79) 62 (82) 53 (77)
Female 30 (21) 14 (18) 16 (23)
ECOG PS, n (%) <0.001
0 102 (70) 64 (84) 38 (55)
1 32 (22) 10 (13) 22 (32)
2 10 (7) 2 (3) 8 (12)
Missing 1 (1) - 1 (1)
Smoking status, n (%) 0.2
Non-smoker 44 (30) 24 (32) 20 (29)
Ex-smoker 61 (42) 36 (47) 25 (36)
Current smoker 37 (26) 15 (20) 22 (32)
Missing 3 (2) 1 (1) 2 (3)
Tumour site, n (%) <0.001
Lip and oral cavity 25 (17) 0 (0) 25 (36)
Nasopharynx 8 (6) 0 (0) 8 (12)
Oropharynx 76 (52) 76 (100) 0 (0)
Hypopharynx 12 (8) 0 (0) 12 (17)
Larynx 24 (17) 0 (0) 24 (35)
Tumour stage, n (%) 0.05
T1 35 (24) 24 (32) 11 (16)
T2 52 (36) 29 (38) 23 (33)
T3 36 (25) 15 (19) 21 (30)
T4 22 (15) 8 (11) 14 (20)
Nodal stage, n (%) <0.001
N0 44 (30) 11 (14) 33 (48)
N1 36 (25) 22 (29) 14 (20)
N2 60 (41) 41 (54) 19 (28)
N3 5 (3) 2 (3) 3 (4)
AJCC stage, n (%) 0.2
I 9 (6) 4 (5) 5 (7)
II 35 (24) 18 (24) 17 (25)
III 74 (51) 44 (58) 30 (43)
IV 27 (19) 10 (13) 17 (27)
p16 tumour status, n (%) <0.001
Negative 48 (51) 7 (16) 41 (80)
Positive 47 (49) 37 (84) 10 (20)
Missing 50 32 19
Treatment, n (%) <0.001
Radiotherapy 17 (12) 10 (13) 7 (10)
Postoperative radiotherapy 29 (20) 3 (4) 26 (38)
Chemoradiotherapy 88 (61) 61 (80) 27 (39)
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Univariate survival analysis showed NLR was associated
to RFS and OS in the total heterogeneous population, oro-
pharyngeal and non-oropharyngeal subpopulations. In the
total population, patients with high NLR had significantly
shorter RFS (p < 0.01) and OS (p < 0.001) and showed a
shorter 1-year RFS and OS (62 % vs 87 % and 83 % vs
93 %, respectively). In the oropharyngeal sub-population,
high NLR patients also showed a poorer RFS (p < 0.01)
and OS (p < 0.01) with shorter 1-year RFS and OS (60 %
vs 97 % and 94 % vs 98 %, respectively, Fig. 1a and c,
Table 3). Similarly, non-oropharyngeal patients had a
lower RFS (p = 0.2) and OS (p < 0.01) and shorter 1-year
RFS and OS (62 % vs 77 % and 69 % vs 87 %, respectively,
Fig. 1b, and d, Table 3).
Predictors of recurrence free survival and overall survival
Univariate survival analysis results for oropharyngeal and
non-oropharyngeal populations are detailed in Table 3.
These analyses showed that ECOG PS, smoking status
and NLR associated to RFS and OS in both populations
and were included in final Cox regression models as p
values were all less than 0.25. Additionally, age was associ-
ated with OS and RFS but only in the oropharyngeal
population. Variables not associated with any survival out-
come from univariate analysis included sex, AJCC stage
and treatment modality. Sex was not analysed in oropha-
ryngeal sub-population as no females had recurrence or
died in the study period.
Multivariable analysis results are described in Table 3.
In oropharyngeal patients, age was no longer associated
with RFS or OS once adjusted for by other variables.
However, patients with poorer ECOG PS (1 or 2) had a
significantly increased hazard of death (4.4 (1.2-16.1),
p = 0.03) and a trend for increased hazard of recurrence
(2.9 (1.0-9.0), p = 0.07). Smoking status was not signifi-
cantly predictive of OS and RFS in oropharyngeal pa-
tients. A high systemic inflammation status, NLR > 5,
was significantly associated to increased hazard of
death (4.6 (1.3-16.8), p = 0.02) and recurrence (3.0 (1.1-
8.5), p = 0.04) in this sub-population.
In non-oropharyngeal patients, poor ECOG PS showed
an increased hazard of death (2.6 (1.0-6.8), p = 0.04) but no
association was seen for RFS. Non-oropharyngeal patients
who continued to smoke through treatment had signifi-
cantly increased hazard, compared to non-smokers and ex-
smokers, for recurrence and death (both p values < 0.001).
An NLR > 5 was significantly associated with increased haz-
ard of death (3.7 (1.3-9.9), p = 0.02) but no strong associ-
ation to RFS was seen.
Discussion
NLR is an easily obtainable, inexpensive marker of sys-
temic inflammation that may assist in clinical decisions re-
garding recurrence and survival in a heterogeneous
HNSCC population. This study aimed to investigate the
predictive role of NLR in an unselected population of
HNSCC patient, but we found that oropharyngeal patients
had significant differences in baseline characteristics com-
pared to non-oropharyngeal patients. As expected from
the growing literature, a very high percentage of oropha-
ryngeal patients were p16 positive (84 %). Thus, we con-
ducted total and sub-site analyses due to the differences
reflecting the potential diverging molecular etiology of
oropharyngeal and non-oropharyngeal disease. In univari-
ate analysis, NLR status did not associate with any other
clinicopathological variables other than neutrophil and
lymphocyte levels in either subgroup as expected. Patients
with an elevated NLR were associated with shorter RFS
and OS in both oropharyngeal and non-oropharyngeal
populations. Univariate survival analysis showed ECOG
PS, smoking status, age and NLR associated with RFS and
OS to varying degrees in both populations. Multivariable
analysis confirmed NLR significantly predicted RFS in
oropharyngeal patients only, while NLR strongly predicted
OS in both sub-populations. Additionally, ECOG PS
significantly showed associations to OS in oropharyngeal
patients and non-oropharyngeal patients. Interestingly,
smoking status remained predictive of RFS and OS only in
non-oropharyngeal patients. This may not be unexpected
considering the low numbers of p16 negative patients in
Table 1 Patient demographics (Continued)
Postoperative chemoradiotherapy 11 (8) 2 (3) 9 (13)
Neutrophils, median counts (range) x 109 cells/L 5.10 (1.10 - 11.90) 4.60 (1.10 - 11.90) 5.30 (2.10 - 11.80) 0.2
Lymphocytes, median counts (range) x 109 cells/L 1.60 (0.20 - 10.70) 1.60 (0.40 - 3.40) 1.70 (0.20 - 10.70) 0.1
NLR, median counts (range) x 109 cells/L 3.11 (0.41 - 29.75) 3.11 (1.30 - 29.75) 3.11 (0.41 - 16.00) 0.9
NLR, n (%) 0.7
Low (≤5) 116 (80) 60 (79) 56 (81)
High (>5) 29 (20) 16 (21) 13 (19)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer and NLR
neutrophil-to-lymphocyte ratio
*, appropriate statistical test (Students t-test, Mann Whitney-U, χ2 test or Fishers exact test) conducted between oropharyngeal and non-oropharyngeal cancer patient
excluding missing values and a, missing values indicated in table
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Table 2 Differences in clinical characteristics for high and low NLR groups
Characteristic All patients (N = 145)a Oropharyngeal (n = 76)a Non-oropharyngeal (n = 69)a
NLR ≤ 5 (n = 116) NLR > 5 (n = 29) p value* NLR≤ 5 (n = 60) NLR > 5 (n =16) p value* NLR≤ 5 (n = 56) NLR > 5 (n = 13) p value*
Age, median years (range) 61 (32–86) 67 (28–86) 0.2 57.5 (32–83) 64 (47–81) 0.07 65 (38–86) 70 (28–86) 0.8
Sex, n (%) 1 1 1
Male 92 (79) 23 (79) 49 (82) 13 (81) 43 (77) 10 (77)
Female 24 (21) 6 (21) 11 (18) 3 (19) 13 (23) 3 (23)
ECOG PS, n (%) 0.5 0.5 0.3
0 84 (73) 18 (62) 51 (85) 13 (81) 33 (60) 5 (38)
1 24 (21) 8 (28) 8 (13) 2 (13) 16 (29) 6 (46)
2 7 (6) 3 (10) 1 (2) 1 (6) 6 (11) 2 (15)
Smoking status, n (%) 0.8 0.9 0.4
Non-smoker 35 (31) 9 (32) 19 (32) 5 (31) 16 (29) 4 (33)
Ex-smoker 48 (42) 13 (46) 29 (49) 7 (44) 19 (35) 6 (50)
Current smoker 31 (27) 6 (21) 11 (19) 4 (25) 20 (36) 2 (17)
Tumour site, n (%) 0.7 - 0.6
Lip and oral cavity 20 (17) 5 (17) 0 (0) 0 (0) 20 (36) 5 (38)
Nasopharynx 8 (7) 0 (0) 0 (0) 0 (0) 8 (14) 0 (0)
Oropharynx 60 (52) 16 (55) 60 (100) 16 (100) 0 (0) 0 (0)
Hypopharynx 9 (8) 3 (10) 0 (0) 0 (0) 9 (16) 3 (23)
Larynx 19 (16) 5 (17) 0 (0) 0 (0) 19 (34) 5 (38)
Tumour stage, n (%) 0.7 0.3 0.8
T1 31 (27) 4 (14) 22 (37) 2 (13) 9 (16) 2 (15)
T2 38 (33) 14 (48) 21 (35) 8 (50) 17 (30) 6 (46)
T3 29 (25) 7 (24) 11 (18) 4 (25) 18 (32) 3 (23)
T4 18 (16) 4 (14) 6 (10) 2 (13) 12 (21) 2 (15)
Nodal stage, n (%) 0.5 0.8 0.3
N0 37 (32) 7 (24) 10 (17) 1 (6) 27 (48) 6 (46)
N1 26 (22) 10 (35) 17 (28) 5 (31) 9 (16) 5 (38)
N2 48 (41) 12 (41) 31 (52) 10 (63) 17 (30) 2 (15)
N3 5 (4) 0 (0) 2 (3) 0 (0) 3 (5) 0 (0)
AJCC stage, n (%) 0.9 0.9 0.5
I 7 (6) 2 (7) 4 (7) 0 (0) 3 (5) 2 (15)
II 27 (23) 8 (28) 14 (23) 4 (25) 13 (23) 4 (31)












Table 2 Differences in clinical characteristics for high and low NLR groups (Continued)
IV 23 (20) 4 (14) 8 (13) 2 (13) 15 (27) 2 (15)
p16 tumour status, n (%) 0.8 0.6 0.2
Negative 39 (51) 9 (47) 5 (14) 2 (25) 34 (85) 7 (64)
Positive 37 (49) 10 (53) 31 (86) 6 (75) 6 (15) 4 (36)
Treatment, n (%) 0.8 0.8 0.8
Radiotherapy 14 (12) 3 (10) 9 (15) 1 (6) 5 (9) 2 (15)
Postoperative radiotherapy 24 (21) 5 (17) 3 (5) 0 (0) 21 (38) 5 (38)
Chemoradiotherapy 68 (59) 20 (69) 46 (77) 15 (94) 22 (39) 5 (38)
Postoperative chemoradiotherapy 10 (9) 1 (3) 2 (3) 0 (0) 8 (14) 1 (8)
Neutrophils, median counts (range) 4.55 (1.10-11.80) 6.80 (3.2-11.90) <0.001 4.40 (1.10-9.30) 7.85 (3.90-11.90) <0.001 5.15 (2.10-2.80) 6.50 (3.20-11.80) <0.01
Lymphocytes, median counts (range) 1.75 (0.50-10.70) 1.10 (0.20-1.70) <0.001 1.65 (0.50-3.40) 1.10 (0.40-1.70) <0.001 1.90 (0.60-10.70) 1.00 (0.20-1.50) <0.001
NLR, median counts (range) 2.69 (0.41-5.00) 6.71 (5.09-29.75) <0.001 2.71 (1.30-4.78) 6.41 (5.09-29.75) <0.001 2.64 (0.41-5.00) 7.00 (5.55-16.00) <0.001
Abbreviations: NLR neutrophil-to-lymphocyte ratio, ECOG PS Eastern Cooperative Oncology Group performance status and AJCC American Joint Committee on Cancer












the oropharyngeal cancer cohort, which may represent the
contribution of smoking habits in the causation of disease
in these patients.
The majority of oropharyngeal patients were p16 posi-
tive in this study and oropharyngeal patients were youn-
ger, had better ECOG PS but had increased nodal spread
compared to non-oropharyngeal patients. Eighty-four
percent of tested oropharyngeal patients had p16 posi-
tive tumours. This percentage is comparable to other
American, Swedish and British studies (summarised in
[32]) although higher than the average rate (~40 %) in
most developed countries. Patients with p16 positive tu-
mours are generally younger [33] and have been noted
to have better ECOG PS and higher nodal stages when
compared to p16 negative patients [34, 35]. The high
prevalence of p16 in the oropharyngeal population most
likely accounts for the younger age and better ECOG PS
compared to non-oropharyngeal patients seen in this
study. The higher nodal stage but improved outcomes in
p16 positive patients is the most likely cause of AJCC
stage not being significant in our study, similar to other
reports [34]. The 3-year OS of oropharyngeal patients was
86 % and 69 % for p16 positive and negative patients re-
spectively, which is comparable to larger studies [36–38].
In vitro studies with p16 positive HNSCC cells lines have
shown that these cells are more radiosensitive [39]. Oro-
pharyngeal patients in our unit are unlikely to undergo pri-
mary surgical intervention due to the perceived high risk
of morbidity if extensive surgery is required. Our excellent
rates of locoregional control in this population further
support this recommendation. However with availability of
transoral robotic assisted surgery [40], a biomarker to pre-
dict a poor performing oropharyngeal subgroup may aid
selection of patients for surgery in the future.
With decreasing smoking rates due to extensive anti-
smoking campaigns, as seen in countries such as Australia,
HPV+ oropharyngeal cancer is increasingly becoming
the prominent subtype. Therefore, additional predictive
Fig. 1 Association of neutrophil-to-lymphocyte ratio to survival outcomes. Neutrophil-to-lymphocyte ratio association to recurrence free survival
in oropharyngeal (a) and non-oropharyngeal (b) patients. Neutrophil-to-lymphocyte ratio association to overall survival in oropharyngeal (c) and
non-oropharyngeal (d) patients. Abbreviations: RFS, recurrence free survival; NLR, neutrophil-to-lymphocyte ratio and OS, overall survival
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biomarkers of clinical outcomes are needed within the
HPV+ or p16 positive oropharyngeal cancer population.
Additionally, classification of patients as HPV+ is not
without difficultly as the various techniques of assessment
produce variable results and there is no universally agreed
classification system. The results of this study show that
on a background of high p16 positive status, elevated NLR
was associated with recurrence and survival outcomes
under univariate analysis and many of the recurrences and
deaths occurred within the first year following radiother-
apy. Multivariable analysis showed that NLR remained a
predictor of OS independent of AJCC stage, tumour site,
treatment modality and sex in oropharyngeal and non-
oropharyngeal sub-populations. Additionally, NLR also
predicted RFS in oropharyngeal patients. The results of
this study identified NLR as a prognostic marker of OS in
an unselected HNSCC cohort, supporting previous findings
from other studies in nasopharyngeal, oral squamous cell
carcinoma and preliminary investigations in unselected
HNSCC cohorts [14, 16–22, 41]. These findings are also
consistent with other cancer types including other head and
neck associated cancers, such as thyroid cancer [42, 43].
The association between NLR and poor OS and recur-
rence is not well understood. However, it is hypothesised
that elevated NLR reflects a more aggressive tumour
phenotype that is immune evasive and/or suppressive. Ele-
vated NLR is more often seen in patients with advanced
disease, as denoted by increased AJCC stage, tumour
depth of invasion or metastatic spread [7]. In our study,
we did not find evidence to confirm NLR was associated
with higher AJCC staging and thus may represent aspects
reflecting immune suppression. Recent analysis conducted
by The Cancer Genome Atlas project, shows that within
the HPV+ population of HNSCC there is an increase in
loss of TNF receptor-associated factor 3 gene and presence
of activating mutations in PIK3CA gene, which enhance
NF-κB signalling and promote a pro-inflammatory micro-
environment [44]. This data supports the role of cancer-
related inflammation in determining the outcomes of
HPV+ HNSCC patients.
Table 3 Univariate and multivariable analysis of OS and RFS in oropharyngeal and non-oropharyngeal patients

















Oropharyngeal patients (n = 76)a
Age (continuous) 1.07 (1.01-1.12) 0.03 1.03 (0.97-1.10) 0.3 1.05 (1.00-1.10) 0.08 1.02 (0.97-1.08) 0.4
Sex (males vs females) No females died No females had recurrence
ECOG PS (0 vs 1–2) 4.08 (1.38-12.12) <0.01 4.36 (1.18-16.06) 0.03 3.33 (1.24-8.89) 0.01 2.92 (0.95-8.97) 0.07
Smoking status <0.01 0.2 0.03 0.3
(current smokerb vs non-smoker) 0.17 (0.04-0.70) 0.34 (0.07-1.64) 0.31 (0.01-0.98) 0.53 (0.15-1.88)
(current smokerb vs ex-smoker) 0.22 (0.07-0.80) 0.28 (0.07-1.09) 0.28 (0.09-0.85) 0.40 (0.12-1.31)
AJCC stage (I-II vs III-IV) 0.78 (0.26-2.34) 0.7 - 0.82 (0.31-2.19) 0.7 -
Treatment (CRT and CRT + surgery
vs RT and RT + surgery)
0.50 (0.46-4.93) 0.5 - 0.63 (0.32-4.00) 0.6 -
NLR (≤5 vs > 5) 4.96 (1.66-14.80) <0.01 4.60 (1.26-16.80) 0.02 3.50 (1.38-8.90) <0.01 3.01 (1.07-8.45) 0.04
Non-oropharyngeal patients (n = 69)c
Age (continuous) 1.02 (0.99-1.06) 0.8 - 1.01 (0.98-1.032) 0.9 -
Sex (males vs females) 1.05 (0.38-2.87) 0.9 - 0.81 (0.33-1.96) 0.6 -
ECOG PS (0 vs 1–2) 3.37 (1.36-8.37) <0.01 2.57 (0.98-6.76) 0.04 1.66 (0.82-3.36) 0.2 1.49 (0.70-3.21) 0.2
Smoking status 0.04 <0.001 0.02 <0.001
(current smokerb vs non-smoker) 0.18 (0.04-0.79) 0.16 (0.03-0.76) 0.35 (0.14-0.87) 0.35 (0.14-0.90)
(current smokerb vs ex-smoker) 0.56 (0.22-1.44) 0.34 (0.12-0.94) 0.38 (0.16-0.90) 0.32 (0.13-0.79)
AJCC stage (I-II vs III-IV) 1.43 (0.56-3.70) 0.5 - 1.53 (0.68-3.42) 0.3 -
Treatment (CRT and CRT + surgery
vs RT and RT + surgery)
0.85 (0.46-2.57) 0.8 - 1.01 (0.50-2.05) 1 -
NLR (≤5 vs > 5) 3.32 (1.36-8.10) <0.01 3.64 (1.34-9.87) 0.02 1.76 (0.79-3.96) 0.2 2.02 (0.83-4.91) 0.1
Abbreviations: HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer, CRT
chemoradiotherapy, RT radiotherapy and NLR neutrophil-to-lymphocyte ratio
*, p value from Kaplan-Meier logrank test; **, p value from Cox regression log likelihood ratio test; a, one patient missing smoking status; b, referent group; and
c, missing 3 patients (two patients missing smoking status and one patient missing ECOG status).
Charles et al. BMC Cancer  (2016) 16:124 Page 10 of 13
In the tumour microenvironment, innate immune cells,
such as neutrophils, macrophages and myeloid derived
suppressor cells, regulate both immune surveillance and
suppression [45]. Increased abundance of these cells is ob-
served in more advanced stages of HNSCC and is associ-
ated with poorer survival [9–11, 46]. Mechanistic studies
conducted in animal models and ex vivo cultures of im-
mune cells from HNSCC patients have demonstrated that
myeloid derived suppressor cells are critical for regulating
the immunosuppressive phenotype and function of co-
operating lymphoid-derived cells in the tumour and circu-
lation [10, 11, 47, 48]. In terms of adaptive immune cells,
the low infiltration of T cells, particularly T regulatory
cells, combined with functional deficits in T helper cells,
cytotoxic T cells and natural killer cells leads to the highly
immune suppressive tumour microenvironment that al-
lows for unrestrained tumour growth [29, 49–52].
Improved understanding of the various interactions of
the tumour and immune system suggest that the ideal
biomarker would measure both the innate and adaptive
immune response, such as the NLR, as this may provide
a better indication of the impact of tumour growth on
both arms of the host immune response. In a mixed can-
cer population (not including HNSCC patients) elevated
NLR was found to positively correlate with circulating
MDSC levels and suppression of lymphocyte function
[53]. However, there is no evidence to date that specific-
ally links elevated NLR to immune cell behaviour in
HNSCC tumours or circulation. Unfortunately, we do
not have blood samples from our patient cohort, but it
would be interesting to investigate circulating NLR
values in studies that have measured peripheral blood
and tumoural MDSC or T cell populations and overall
survival to clarify the biological relationships between
NLR and immune suppression in cancer.
More recently, the NLR has been suggested as a Phase
I clinical trial patient selection tool by the Royal Mars-
den Hospital, UK [54]. Pharmacological inhibitors of key
immunosuppressive mediators (anti-PD1 or PD ligand 1
antibodies, STAT3 and PDE5 inhibitors) have been
shown to reduce the number and function of MDSC,
Tregs and/or immune T cell-mediated anti-tumour re-
sponses in mice and are increasingly being investigated
in clinical trials [11, 55, 56] . New data from the The
Cancer Genome Atlas [44] has also suggested novel
pathways for intervention, such as the PIK3 pathway due
to activating mutations in PI3KCA for HPV+ cancers.
Thus, NLR could be useful as inclusion criteria for clinical
trial participation investigating these molecular targeted
and immune modulating therapies.
In addition to NLR predicting survival outcomes,
other exploratory variables including smoking status and
ECOG PS were predictive of RFS and OS. Smoking sta-
tus was a significant predictor of RFS and OS but only
in the non-oropharyngeal population. Smoking is not
only a risk factor for the development of head and neck
cancer but patients who maintain smoking during treat-
ment are also at increased hazard of worse clinical out-
comes [57]. Patients with poorer ECOG PS had an
increased hazard of death in both sub-populations which
has been suggested previously in HNSCC [58] and ob-
served in other advanced cancers [59].
This study is limited by inherent selection bias due to
the retrospective analysis of this study and being con-
ducted in one metropolitan area hospital. However, this co-
hort reflects the heterogeneous nature of HNSCC in the
community. Our population has a large proportion of p16
positive oropharyngeal tumours with comparable clinical
outcomes to other international sites. Similar to other can-
cers (breast, colon, lung), the management of this patient
group will change in the future from one single treatment
to individualised treatments based on patient and tumour
characteristics. One of the main limitations of the study
was the incomplete analysis of p16 status in all patients. It
would be of interest to investigate if the p16 positive oro-
pharyngeal patients alone mimic the results of the total
oropharyngeal population. Due to the high rates of positive
patients it is probable that the results would be similar, un-
fortunately, our study did not have large enough numbers
of tested patients to confirm this assumption. Although all
patients had radiotherapy and chemotherapy at the one
site, surgery was conducted over multiple hospital sites.
Unfortunately, we were unable to collect diagnostic blocks
from some surgical sites and private pathology laboratories.
As such, we assumed based on the lack of significant differ-
ences in major covariates in the tested and untested popu-
lations and consistency with overall rates of p16 positive
oropharyngeal cancer patients in our local area health ser-
vice, that p16 status was not a statistically relevant covari-
ate in our patient population. Using this assumption we
may have missed an important interaction between p16
and NLR. In addition, we used p16 immunohistochemistry
as the method for HPV positivity. There is a known dis-
cordance between DNA and protein detection methods
[60, 61]. The p16 positive immunohistochemistry staining
method, as performed in this paper, assumes that the over-
expression of p16 is predominantly due to HPV infections,
however HPV-independent mechanisms such as alter-
ations in the retinoblastoma pathway may also drive p16
expression [44]. A variety of DNA-based and immunohis-
tochemical methods have been used in various studies and
consensus methods are being developed.
Conclusions
We have conducted an extensive analysis of clinicopatho-
logical variables and identified that NLR, ECOG PS and
smoking status are predictive of OS and RFS in sub-
populations of a heterogeneous HNSCC population. NLR
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is an inexpensive, routinely available blood test based
marker that would be a valuable tool for use in clinical
decision-making. The association of NLR to RFS and OS
is believed to relate to potential roles of inflammation in
regulating cancer progression and immune evasion. Thus,
NLR may help identify patients at high risk of recurrence
and early death and indicates that this subset of patients
may require additional treatments in order to improve
their prognostic outlook. Additionally, the NLR has poten-
tial utility in selecting patient populations in clinical trials
using immune modulating therapies. Further larger pro-
spective studies are required in HNSCC populations to
improve the clinical outcomes of all patients.
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